Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Pfizer to offer all its drugs not-for-profit to 45 lower-income countries

Company launches ‘healthier world’ accord in Davos and speaks to other pharma firms about similar steps

The Guardian - UK

Davos updates | Pfizer offers low-cost drugs to poor nations

Pfizer says it will provide nearly two dozen products, including its top-selling COVID-19 vaccine and treatment, at not-for-profit prices in some of the world’s poorest countries

The Independent UK

Cambodia, Laos to benefit as Pfizer slashes drug prices for poorest nations

Pfizer Inc plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, including Cambodia and Laos, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer.

Bangkok Post

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer to sell all its patented drugs at nonprofit price in low-income countries

Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.

Reuters

Pfizer to offer low-cost medicines, vaccines to poor nations

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries

The Independent UK

Germany's vaccine panel says one COVID shot enough for children

Germany's vaccine advisory panel on Tuesday said one COVID-19 shot was enough for healthy five- to 11-year-olds because most of them had already undergone an infection, maintaining its cautious approach.

Reuters

Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC). The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year. UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What happened to the AstraZeneca vaccine? How blood clot scares tarnished its reputation

While the AZ./Oxford vaccine has all but vanished from richer countries, it has continued to be rolled out elsewhere

Wales Online

China's bet on homegrown mRNA vaccines holds back nation

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19

The Independent UK

Morning Digest | Quad leaders meet in Tokyo at 2nd in-person summit; India to be the leader of green hydrogen, says Puri in Davos, and more

A select list of stories to read before you start your day

The Hindu

What's next for COVID-19 vaccines for youngest US children

Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news

The Independent UK

What happened to the AstraZeneca vaccine? Now rare in rich countries, it’s still saving lives around the world

The AstraZeneca vaccine, developed in partnership with the University of Oxford, was one of the first vaccines available for use in the UK and around the world during the COVID pandemic.

The Conversation

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Benzinga

Pfizer COVID shot seems protective for children under 5 in early data

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Covid vaccine: Pfizer says three doses enough to protect children under 5

Three doses of Pfizer’s Covid-19 vaccine will offer strong protection for children younger than 5, the company announced on Monday.

WEKU

If Pfizer's data pans out, when will little kids get the COVID-19 vaccine?

Pfizer plans to submit new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.

Reuters

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

The Independent UK

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

Get all your
news in one place.

100's of premium titles.
One news app.

Axios

Pfizer says COVID vaccine more than 80% effective in kids under 5

Pfizer reported three doses of its vaccine in kids under five produced a strong immune response and was safe.

WEKU

Coronavirus FAQ: I took Paxlovid. I felt better. Then symptoms rebounded. What's up?

The antiviral drug is prescribed to those at risk of severe disease. It's been credited with reducing hospitalizations. But then there's the "Paxlovid rebound."

Benzinga

This Is What Whales Are Betting On Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years

The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX). Following the recommendation, many of the nation's doctors, pharmacies, and other vaccination sites are expected to begin offering the extra doses to the 28 million U.S. children…

Daily Record

High blood pressure tablets recalled in Scotland amid 'impurity' concerns

Twelve batches of Pfizer Accupro have been removed from the shelves.

WEKU

The CDC is urging a Pfizer booster for children ages 5 to 11

The Centers for Disease Control and Prevention's advice opens a third COVID-19 shot to healthy elementary-age kids — just like what is already recommended for everybody 12 and older.

Al Jazeera

US panel recommends COVID booster jab for children aged 5 to 11

Just more than 29 percent of US children in the age group have received two doses of Pfizer-BioNTech’s vaccine to date.

1 … 51 52 53 54

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

346 stories

PFE

345 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.